A1 and A3 adenosine receptor agonists: an overview

Bibliography

• FREDHOLM B, ABBRACCHIO MP, BURNSTOCK G et al: Nomenclature and classification of purinoceptors. Pharm. Rev. (1994) 46:143–156.
   PubMed Web of Science ®Google Scholar
• ••Fundamental for the nomenclature.
   Google Scholar
• PALMER TM, STILES GL: Adenosine receptors. Neuro- pharmacology (1995) 34:683–694.
   Google Scholar
• •Interesting biological characterisation.
   Google Scholar
• OLAH ME, REN H, STILES GL: Adenosine receptors: pro- tein and gene structure. Arch. Int. Pharmacodyn. (1995) 329:135–150.
   PubMedGoogle Scholar
• MAHAN LG, MCVITTIE LD, SMYK-RANDALL EM et al.: Cloning and expression of an Ai adenosine receptor from rat brain. Mol. Pharmacol (1991) 40:1–7.
   PubMed Web of Science ®Google Scholar
• TOWNSEND-NICHOLSON A, SHINE J: Molecular cloning and characterization of a human brain A1 adenosine receptor cDNA. Mol. Brain Res. (1992) 16:365–370.
   PubMedGoogle Scholar
• LIBERT F, VAN SANDE J, LEFORT A et al: Cloning andfunctional characterization of a human A1 adenosine receptor. Biochem. Biophys. Res. Commun. (1992) 187:919–926.
   PubMedGoogle Scholar
• •Good biological characterisation.
   Google Scholar
• OLAH ME, REN H, OSTROWSKI J, JACOBSON KA, STILES GL: Cloning, expression, and characterization of the unique bovine Ai adenosine receptor. J. Biol. Chem. (1992) 276:10764–10770.
   Google Scholar
• POULSEN SA, QUINN RJ: Adenosine receptors: new op- portunities for future drugs. Bioorg. Med. Chem. (1998) 6:619–641.
   PubMed Web of Science ®Google Scholar
• ••General overview of possible therapeutic applications.
   Google Scholar
• BELARDINELLI L: Adenosine system in the heart. Drug Dev. Res. (1993) 28:263–267. Interesting biological characterisation.
   Google Scholar
• WINDSHEIF U: Purinoceptors: from history to recent progress. A review. J. Pharm. Pharmacol (1996) 48:993-1011. An overview of the physiological role of adenosine.
   Google Scholar
• GUNGOR T, MALABRE P, TEULON JM et al.: N6-substituted adenosine receptor agonists. Synthesis and pharmacological activity as potent antinocicep-tive agents. J. Med. Chem. (1994) 37:4307–4316.
   Google Scholar
• ISHIKAWAJ, MITANI H, BANDOH T et al: Hypoglycemic and hypotensive effects of 6-cyclohexy1-2'-0-methyl--adenosine, an adenosine Ai receptor agonist in spon-taneously hypertensive rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. (1998) 31:3–9.
   Google Scholar
• MERKEL LA, HAWKINS ED, COLUSSI DJ et al: Cardiovas- cular and antilipolytic effects of the adenosine agonist GR 79236. Pharmacology (1995) 51:224–236.
   PubMed Web of Science ®Google Scholar
• VAN SCHAICK EA, DE GREEF HJMM, LANGEMEIJER MWE et al.: Pharmacokinetic-pharmacodynamic modelling of the antilipolytic and anti-ketotic effects of the adenosine Ai receptor agonist N6-(p-sulphophenyl)adenosine in rats. Br. J. Pharmacol (1997) 122:525–533.
   PubMed Web of Science ®Google Scholar
• TOOMBS CF, MCGEE S, JOHNSTON WE et al.: Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimula-tion during ischemia. Circulation (1992) 86:986–994.
   Google Scholar
• ••Important therapeutic application.
   Google Scholar
• THORNTON JD, LIU GS, OLSSON RA, DOWNEY JM: Intra- venous pretreatment with Ai selective adenosine ana-logs protects the heart against infarction. Circulation (1992) 85:659–665.
   PubMed Web of Science ®Google Scholar
• •Important therapeutic application.
   Google Scholar
• EGAN JJ, GREENBERG AS, CHANG MK et al.: Mechanism of hormone-stimulated lipolysis in adipocytes: trans-location of hormone-sensitive lipase to the lipid stor-age droplet. Proc. Natl. Acad. Sci. USA (1992) 89:8537–8541.
   PubMed Web of Science ®Google Scholar
• ZHOU QY, LI CY, OLAH ME et al.: Molecular cloning and characterization of an adenosine receptor - the A3 adenosine receptor. Proc. Nati Acad. Sci. USA (1992) 89:7432–7436.
   PubMed Web of Science ®Google Scholar
• ••Interesting biological characterisation.
   Google Scholar
• ABBRACCHIO MP, BRAMBILLA R, KIM HO et al.: G-protein-dependent activation of phospholipase-C by adenosine A3 receptor in rat brain. Mol Pharmacol (1995) 48:1038–1045.
   PubMed Web of Science ®Google Scholar
• •Interesting biological characterisation.
   Google Scholar
• LINDEN J: Cloned adenosine A3 receptors - pharmacol- ogical properties, species differences and receptor functions. Trends Pharmacol. Sci. (1994) 15:298–306.
   PubMed Web of Science ®Google Scholar
• ••Complete study of the receptor.
   Google Scholar
• HANNON JP, PFANNKUCHE HJ, FOZARD JR: A role for mast cells in adenosine A3 receptor-mediated hy-potension in the rat. Br. J. Pharmacol (1995) 115:945–952.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, NIKODIJEVIC O, SHI D et al.: A role for central A3 adenosine receptors: mediation of behav-ioral depressant effects. FEBS Lett. (1993) 336:57–60.
   Google Scholar
• LUBITZ DKJV, CARTER MF, DEUTSCH SI et al.: The effects of adenosine A3 receptor stimulation on seizures in mice. Eur. j Pharmacol (1995) 275:23–29.
   PubMedGoogle Scholar
• LUBITZ DKJV, LIN RCS, POPIK P et al.: Adenosine A3 re- ceptor stimulation and cerebral ischemia. Eur. J. Phar-macol (1994) 263:59–67.
   PubMedGoogle Scholar
• •Interesting physiological role.
   Google Scholar
• VAN SCHAICK EA, JACOBSON KA, KIM HO et al.: Haemo- dynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-C1-IB-MECA in conscious rat. Eur. J. Pharmacol (1996) 308:311–314.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B, SPALLUTO G, JI XD eta].: Novel N6-(substituted-phenylcarbamoy0 adenosine-5'-uron-amides as potent agonists for A3 adenosine receptors. J. Med. Chem. (1996) 39:802–806.
   Google Scholar
• BARALDI PG, CACCIARI B, PINEDA DE LAS INFANTAS MJ et al.: Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as Ai and A3 adeno-sine receptor agonists. J. Med. Chem. (1998) 41:3174–3185.
   Google Scholar
• ABBRACCHIO MP, CERUTI S, BRAMBILLA R etal.: Modula- tion of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Patho-physiological significance and therapeutic implica-tions for neurodegenerative disorders. Ann. NY Acad. Sci. (1997) 825:11–22.
   Google Scholar
• •Interesting physiological role.
   Google Scholar
• KOHNO Y, SEI Y, KOSHIBA M eta].: Induction of apopto-sis in HL-60 human promyelocytic leukemia cells by selective adenosine A3 receptor agonists. Biochem. Bio-phys. Res. Commun. (1996) 219:904–910.
   Google Scholar
• YAO Y, SEI Y, ABBRACCHIO MP et al.: Adenosine A3 re-ceptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem. Biophys. Res. Commun. (1997) 232:317–322.
   PubMed Web of Science ®Google Scholar
• BOUMA MG, JEUNHOMME TM, BOYLE DL et al: Adeno- sine inhibits neutrophil degranulation inactivated hu-man whole blood: involvement of adenosine A2 and A3 receptors. J. Immunol (1997) 158:5400–5408.
   PubMed Web of Science ®Google Scholar
• FOZARD JR, PFANNKUCHE HJ, SCHUURMAN HJ: Mast cell degranulation following adenosine A3 receptor activa-tion in rats. Eur. J. Pharmacol (1996) 298:293–297.
   PubMed Web of Science ®Google Scholar
• SHEPHERD RK, LINDEN J, DULING HR: Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ. Res. (1996) 78:627–634.
   Google Scholar
• STRICKLER J, JACOBSON KA, HANG BT: Direct precondi-tioning of cultured chick ventricular myocytes: novel functions of cardiac adenosine A2A and A3 receptors. J. Clin. Invest. (1996) 98:1773–1779.
   PubMedGoogle Scholar
• JACOBSON KA: Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. (1998) 19:184–191.
   PubMed Web of Science ®Google Scholar
• •Interesting study of biological activity.
   Google Scholar